Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Acquisition Reaction

<< Previous

Bullboard Posts

Next >>

Comment by mjh9413on Aug 09, 2024 12:10am

176 Views

Post# 36170774

RE:Acquisition Reaction

All sounds good at first blush but I see the comment in NR that
"Spinosad, a topical treatment for both head lice and scabies. There are currently no generic alternatives for these products"
but I also see Good Rx has a voucher for a generic version. The costs of both are 'interesting'. Also contrast permethrin cost, whch they say is also used for scabies not (lust) head lice.

Wiil be interesting how they deal with large staffing at ParaPRO and so on, Anyone know details of new credit facility, fees, interest rate and so on?

I actually like the Swedish MOB-15 product's potential. Wish I bought back then!!

I am not long but have on watch list,

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project